Current Hypertension Reports

, Volume 15, Issue 1, pp 25–30 | Cite as

Update on the Angiotensin AT2 Receptor

  • Claudia A. McCarthy
  • Robert E. Widdop
  • Kate M. Denton
  • Emma S. Jones
Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Abstract

It is quite well established that activation of the AT2 receptor (AT2R) provides a counter-regulatory role to AT1R overactivity, particularly during pathological conditions. Indeed, a potential therapeutic role for the AT2R is currently being promulgated with the introduction of novel AT2R ligands such as compound 21 (C21). In this brief review, we will focus on recent evidence to suggest that AT2R exhibits promising organ protection in the context of the heart, kidney and brain, with inflammation and gender influencing outcome. However, this field is not without controversy since the ‘flagship’ ligand C21 has also come under scrutiny, although it is safe to say there is much evidence to support a potentially important role of AT2R in a number of cardiovascular diseases. This report updates recent data in this field.

Keywords

Angiotensin peptides AT2 receptor AT2Angiotensin II Angiotensin III Compound 21 C21 Ang peptides AT2R agonists Beta-substituted amino acids Vascular Antifibrotic Neuroprotection Kidney Brain function Organ protection Blood pressure Hypertension 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70–88.PubMedCrossRefGoogle Scholar
  2. 2.
    Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38:1150–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Wharton J, Morgan K, Rutherford RA, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323–36.PubMedGoogle Scholar
  5. 5.
    Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Jones ES, Vinh A, McCarthy CA, et al. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316.PubMedCrossRefGoogle Scholar
  7. 7.
    Hein L, Meinel L, Pratt RE, et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol. 1997;11:1266–77.PubMedCrossRefGoogle Scholar
  8. 8.
    Widdop RE, Matrougui K, Levy BI, et al. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40:516–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Porrello E, Delbridge L, Thomas W. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21:501–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995–6008.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523–32.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Rompe F, Artuc M, Hallberg A, et al. Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor {kappa}B. Hypertension. 2010;109:147843. The first report that identified mechanisms linking AT 2 receptor stimulation with antiinflammatory effects.Google Scholar
  16. 16.
    Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142:821–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112–6.PubMedCrossRefGoogle Scholar
  18. 18.
    •• Bosnyak S, Welungoda IK, Hallberg A, et al. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709–16. Comprehensive dose-ranging study of the in vitro and in vivo vascular effects of Compound 21.PubMedCrossRefGoogle Scholar
  19. 19.
    • Verdonk K, Durik M, Abd-Alla N, et al. Compound 21 Induces Vasorelaxation via an Endothelium- and Angiotensin II Type 2 Receptor-Independent Mechanism / Novelty and Significance. Hypertension. 2012;60:722–9. A controversial study that reported off-target effects of the AT 2 receptor agonist Compound 21, albeit at concentrations up to 10,000-fold higher than its affinity at AT 2 receptors.PubMedCrossRefGoogle Scholar
  20. 20.
    Moltzer E, Verkuil AV, van Veghel R, et al. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension. 2010;55:516–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Henrion D. Why do we need a selective angiotensin II type 2 receptor agonist? Hypertension. 2012;60:616–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Regoli D, Park WK, Rioux F. Pharmacology of angiotensin. Pharmacol Rev. 1974;26:69–123.PubMedGoogle Scholar
  23. 23.
    de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–72.PubMedGoogle Scholar
  24. 24.
    •• Bosnyak S, Jones ES, Christopoulos A, et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci. 2011;121:297–303. First study to directly compare a range of Ang peptides in the same study to determine AT 2:AT 1 receptor selectivity.PubMedGoogle Scholar
  25. 25.
    Padia SH, Kemp BA, Howell NL, et al. Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor Mediated Natriuresis In Rats. Hypertension. 2008;51:460–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Padia SH, Kemp BA, Howell NL, et al. Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin Type 1 Receptor-Blocked Rats. Hypertension. 2007;49:625–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Padia SH, Howell NL, Siragy HM, et al. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Vinh A, Widdop RE, Drummond GR, et al. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008;77:178–87.PubMedCrossRefGoogle Scholar
  30. 30.
    • Bosnyak S, Widdop RE, Denton KM, et al. Differential mechanisms of Ang (1–7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens. 2012;2012:192567. Striking difference in the vascular phenotype of Ang (17) given acutely to either young-adult or aged conscious rats.PubMedGoogle Scholar
  31. 31.
    Rosenstrom U, Skold C, Lindeberg G, et al. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4–5 of angiotensin II. J Med Chem. 2004;47:859–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Johannesson P, Erdelyi M, Lindeberg G, et al. AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J Med Chem. 2004;47:6009–19.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Murugaiah AM, Wu X, Wallinder C, et al. From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists. J Med Chem. 2012;55:2265–78. A recent report of the development of a nonpeptide AT 2 receptor antagonist by minor substitutions to the structure of Compound 21.PubMedCrossRefGoogle Scholar
  34. 34.
    •• Jones ES, Del Borgo MP, Kirsch JF, et al. A Single beta-Amino Acid Substitution to Angiotensin II Confers AT(2) Receptor Selectivity and Vascular Function. Hypertension. 2011;57:570–6. Describes how a simple beta-amino acid substitution into the Ang II molecule dramatically alters AT 2:AT 1 receptor selectivity and function.PubMedCrossRefGoogle Scholar
  35. 35.
    Ocaranza MP, Lavandero S, Jalil JE, et al. Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens. 2010;28:1054–64.PubMedCrossRefGoogle Scholar
  36. 36.
    Flores-Munoz M, Smith NJ, Haggerty C, et al. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol. 2011;589:939–51.PubMedCrossRefGoogle Scholar
  37. 37.
    • Flores-Munoz M, Work LM, Douglas K, et al. Angiotensin-(1–9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension. 2012;59:300–7. Antifibrotic effect ascribed to chronic infusion of Ang (19) acting at AT 2 receptors, although a contribution by other metabolized Ang peptides and mechanisms needs to be fully ruled out.PubMedCrossRefGoogle Scholar
  38. 38.
    Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87:E1–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Padia SH, Kemp BA, Howell NL, et al. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension. 2012;59:437–45.PubMedCrossRefGoogle Scholar
  40. 40.
    Salomone LJ, Howell NL, McGrath HE, et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension. 2007;49:155–61.PubMedCrossRefGoogle Scholar
  41. 41.
    •• Kemp BA, Bell JF, Rottkamp DM, et al. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012;60:387–95. Current paper from a series of publications that shows Ang III, but not Ang II or Ang (17), causes AT2 receptor mediated natriuresis.PubMedCrossRefGoogle Scholar
  42. 42.
    Brown RD, Hilliard LM, Head GA, et al. Sex Differences in the Pressor and Tubuloglomerular Feedback Response to Angiotensin II. Hypertension. 2012;59:129–35.PubMedCrossRefGoogle Scholar
  43. 43.
    Sampson AK, Moritz KM, Jones ES, et al. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52:666–71.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Hilliard LM, Nematbakhsh M, Kett MM, et al. Gender Differences in Pressure-Natriuresis and Renal Autoregulation Role of the Angiotensin Type 2 Receptor. Hypertension. 2011;57:275–82. A study demonstrating the greater functional role of AT 2 receptors in renal vasculature in female, as compared to male, rats.PubMedCrossRefGoogle Scholar
  45. 45.
    •• Hilliard LM, Jones ES, Steckelings UM, et al. Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal Function. Hypertension. 2012;59:409–14. First report showing enhanced AT 2 receptor-mediated renal vasodilator response to Compound 21 in female, as compared to male, rats.PubMedCrossRefGoogle Scholar
  46. 46.
    •• Rehman A, Leibowitz A, Yamamoto N, et al. Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension. 2012;59:291–9. One of the first studies to show cardiac antifibrotic effects following chronic treatment with Compound 21, although its potential inhibition by the AT 2 receptor antagonist PD123319 was not examined.PubMedCrossRefGoogle Scholar
  47. 47.
    •• Paulis L, Becker STR, Lucht K, et al. Direct Angiotensin II Type 2 Receptor Stimulation in N-Nitro-l-Arginine-Methyl Ester- Induced Hypertension. Hypertension. 2012;59:485–92. One of the first studies to show vessel remodeling following chronic treatment with Compound 21, although its potential inhibition by the AT 2 receptor antagonist PD123319 was not examined.PubMedCrossRefGoogle Scholar
  48. 48.
    • Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension. Hypertension. 2011;57:308–13. One of the first studies to show anti-inflammatory effects of Compound 21 in the kidney after short-term treatment with Compound 21.PubMedCrossRefGoogle Scholar
  49. 49.
    Gelosa P, Pignieri A, Fändriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Foulquier S, Steckelings UM, Unger T. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep. 2012;14:403–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Jehle AB, Xu Y, Dimaria JM, et al. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J Cardiovasc Pharmacol. 2012;59:363–8.PubMedCrossRefGoogle Scholar
  52. 52.
    McCarthy CA, Vinh A, Callaway JK, et al. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40:1482–9.PubMedCrossRefGoogle Scholar
  53. 53.
    •• McCarthy CA, Vinh A, Broughton BR, et al. Angiotensin II Type 2 Receptor Stimulation Initiated After Stroke Causes Neuroprotection in Conscious Rats. Hypertension. 2012, Oct 22 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given centrally 6 hours after stroke in conscious spontaneously hypertensive rats, still evoked neuroprotection. Google Scholar
  54. 54.
    •• Lee S, Brait V, Arumugam T, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012, 4: Aug 24 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given peripherally at the time of ischaemia/reperfusion in anaesthetised mice, evoked neuroprotection.Google Scholar
  55. 55.
    Shraim N, Mertens B, Clinckers R, et al. Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J Neurosci Methods. 2011;202:137–42.PubMedCrossRefGoogle Scholar
  56. 56.
    • Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin-(1–7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084–96. First report showing that Ang (17) can also evoke neuroprotective effects.PubMedGoogle Scholar
  57. 57.
    Tota S, Hanif K, Kamat PK, et al. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology (Berl). 2012;222:185–202.CrossRefGoogle Scholar
  58. 58.
    •• Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32:248–55. First report on the improved cognitive effects of Compound 21.PubMedCrossRefGoogle Scholar
  59. 59.
    • Horiuchi M, Iwanami J, Mogi M. Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci. 2012;123:193–203. An excellent recent review summarising a number of aspects of nonclassical Ang signaling that are not covered in the current update.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Claudia A. McCarthy
    • 1
  • Robert E. Widdop
    • 1
  • Kate M. Denton
    • 2
  • Emma S. Jones
    • 1
  1. 1.Department of PharmacologyMonash UniversityClaytonAustralia
  2. 2.Department of PhysiologyMonash UniversityClaytonAustralia

Personalised recommendations